Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.
Unlike the investment banks, we created StockStory to provide independent analysis that helps you determine which companies are truly worth following. Keeping that in mind, here is one stock where Wall Street’s excitement appears well-founded and two where analysts may be overlooking some important risks.
Two Stocks to Sell:
Byrna (BYRN)
Consensus Price Target: $34.80 (181% implied return)
Providing civilians with tools to disable, disarm, and deter would-be assailants, Byrna (NASDAQ: BYRN) is a provider of non-lethal weapons.
Why Does BYRN Fall Short?
- Poor expense management has led to an operating margin of -0.1% that is below the industry average
- Cash-burning tendencies make us wonder if it can sustainably generate shareholder value
- Depletion of cash reserves could lead to a fundraising event that triggers shareholder dilution
At $12.38 per share, Byrna trades at 27.1x forward P/E. Read our free research report to see why you should think twice about including BYRN in your portfolio.
Trupanion (TRUP)
Consensus Price Target: $46.25 (60.8% implied return)
Born from a vision to help pet owners avoid economic euthanasia when faced with expensive veterinary bills, Trupanion (NASDAQ: TRUP) provides medical insurance for cats and dogs through data-driven, vertically-integrated products priced specifically for each pet's unique characteristics.
Why Do We Think Twice About TRUP?
- Book value per share stagnated over the last five years, limiting its ability to leverage its balance sheet to make additional investments
- Negative return on equity shows management lost money while trying to expand the business
Trupanion is trading at $28.77 per share, or 2.8x forward P/B. Dive into our free research report to see why there are better opportunities than TRUP.
One Stock to Buy:
Remitly (RELY)
Consensus Price Target: $21.50 (24.5% implied return)
With Amazon founder Jeff Bezos as an early investor, Remitly (NASDAQ: RELY) is an online platform that enables consumers to safely and quickly send money globally.
Why Is RELY a Good Business?
- Active Customers have grown by 29.2% annually, allowing for more profitable cross-selling opportunities if it can build complementary products and features
- Incremental sales significantly boosted profitability as its annual earnings per share growth of 108% over the last three years outstripped its revenue performance
- Free cash flow margin jumped by 34.7 percentage points over the last few years, giving the company more resources to pursue growth initiatives, repurchase shares, or pay dividends
Remitly’s stock price of $17.28 implies a valuation ratio of 9.6x forward EV/EBITDA. Is now the right time to buy? Find out in our full research report, it’s free.
High-Quality Stocks for All Market Conditions
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren't just high-quality businesses. Something is happening with them right now. Elite fundamentals meeting near-term momentum — both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week's Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.
